Predictmedix Inc. announced the results of its latest study using the company's proprietary AI technology (patent pending) to detect alcohol and cannabis impairment, along with an upcoming trial in a North American clinical setting. Predictmedix's proprietary impairment detection technology detects cannabis and alcohol impairment using AI algorithms based on a multiparametric approach to identify unique features from multispectral imaging and voice analysis. The Company filed a US patent in 2020.

The technology does not require biological fluids and is contactless, quick, and easy to use, cost-effective, and provides immediate results. In a supervised environment with 128 participants, the Company's proprietary AI technology demonstrated a 79-87% efficacy in identification of cannabis impairment and 76-92% efficacy in identification of alcohol impairment (depending on the amount of cannabis or alcohol consumed by the subject). Building on the datasets and insights from this and other previous research and studies, the company excited to commence an additional clinical study in February 2022 with researchers and doctors at a North American hospital.

If the study shows similar results, the hospital study will provide a third-party independent validation of the Company's impairment detection solution ahead of commercial launch. The data collected can be used by the Company to further fine-tune the AI algorithms. The results of the independently validated study will be published in a peer-reviewed medical journal. The Company has engaged an accredited consulting firm to assist the Company in seeking classification of the technology as a class II medical device in the US.